Drug Development Cancer Treatment Targeted Therapy Regenerative Medicine Natural Therapies Pharmacology Cell Therapy Immunotherapy Monoclonal Antibodies Metabolic Therapies Treatment Strategies Drug Discovery Innovative Treatments Age-related Disorders Microbiome Treatment Indications Obesity Neurostimulation Rehabilitation Strategies Microbiota-Based Therapies Antiviral Therapies Small Molecule Drugs Protein Therapy RNA Medicine Obesity Treatments Disease Treatment Behavioral Interventions Nanobody Therapy Sleep Disorders Symptomatic Treatments Mitochondrial Disorders Diabetes Treatment Pulmonary Diseases Pharmaceuticals Chronic Conditions Combination Therapy Biotechnology Cardiology Drug Delivery Neuropsychiatric Symptoms Metabolic Diseases Cardiovascular Health Cellular Therapies Non-invasive Treatments Treatment Development Targeted Treatments Biotherapeutics Amylin Analog Phage Therapy Cancer Therapy Immunomodulation Memory Treatment Drug Applications Pain Treatment Disease Intervention Microbiome-based Therapies Host-directed Therapeutics Microbiome Therapy Drug Formulations Topical Treatments Precision Medicine GLP-1 Therapies Osteoarthritis Rehabilitation Gene Therapy Treatment Methods Cardiology Treatments Viral Infections
The authors link a leucine‑derived acetyl‑CoA pathway to autophagy failure and protein aggregation and urge targeting upstream metabolic or inflammatory nodes as possible therapeutic directions.
